Williams & Connolly successfully represented Alcon Research, Ltd. in a patent infringement action under the Hatch-Waxman Act relating to Alcon’s Pazeo®, an ophthalmic drug product used to treat allergic conjunctivitis. After a four day bench trial in October 2017, on March 1, 2018, the U.S. District Court for the District of Delaware ruled in favor of our client, finding that Watson and Lupin had not proven by clear and convincing evidence that the patent covering the active pharmaceutical ingredient was invalid.
The team representing Alcon included Adam Perlman, Christopher Mandernach, Joelle Justus, and Christopher Suarez.